BTW - personally I think they would be better served in developing broad spectrum antivirals. Some have already been proposed but don't seem to have a lot of funding behind them at the moment.
A broad-spectrum antiviral would be the holy grail. But it's much harder to create broad-spectrum antiviral effects than it is to produce broad-spectrum antibacterial action. We have lots of broad-spectrum antibiotics, but not much in the way of broad-spectrum antivirals.
I've spent the last 10 years hunting for compounds that might have action against my virus, coxsackievirus B4. This virus I believe underpins my chronic disease of ME/CFS, so if an effective antiviral could be found, I could be cured, or at least have much improved health.
In my research over 10 years, I found at least 120 substances (such as supplements, herbal extracts, off-label drugs, compounds in the research pipeline, etc) that have in vitro antiviral effects against my virus, demonstrated in studies. But for various reasons, none of these pan out to working in vivo.
So I still have not found that elusive antiviral to cure my chronic disease. Coxsackievirus B is actually linked to a number of diseases, so if an effective antiviral were found, we might be able to cure a whole host of illness.
But that is easier said than done, and once you've spent 10 years looking for answers, you begin to understand how difficult it is.
But we should remain optimistic, because maybe some new biomedical technology will come along in future that enables us to target all viruses in a broad-spectrum manner.
The promise of such a technology is not just protection from future pandemics, but theoretically this tech could cure a wide range of chronic diseases and cancers, since almost every everyday chronic disease has been linked to an ongoing low-level viral infection in the tissues of the diseased organs.
So a golden age of perfect health may await us if we can figure out how to fully eliminate viral infections from the body tissues.
Edited by Hip, 08 August 2023 - 03:21 PM.